Patent landscape report on assistive devices for visually and hearing impaired persons
Download 13.52 Mb.
|
- Navigate this page:
- Relevant News and Articles
- MED-EL ELECTROMEDIZINISCHE GERAETE GMBH
- MED-EL Hearing Implant Solutions
- ALLERGAN
SEIKO EPSONThe company sells its products primarily in Japan, the Americas, Europe, and Asia/Oceania. Seiko Epson Corporation was founded in 1942 and is headquartered in Suwa, Japan.157 Seiko Epson Corporation is primarily involved in the manufacture of various equipments. The Information Equipment segment manufactures and offers printers, such as inkjet printers, page printers and dot matrix printers, among others; visual products, such as liquid-crystal projectors and high temperature poly-silicon thin-film transistor (TFT) liquid crystal panels for liquid-crystal projectors, personal computers (PCs). The Printer segment is engaged in the development, manufacture and sale of products that implement total solutions for color digital data input and output. The Visual Products segment is engaged in the development, manufacture and sale of crystal devices including liquid crystal projectors, high temperature poly-silicon TFT liquid crystal panels of liquid crystal projectors. The other segment is engaged in the sale of PCs.158 An example of Seiko Epson’s innovative contribution to this technology field can be seen in patent US7556444B2 entitled “Embossing control method, program, braille-embossing apparatus, and character-information-processing apparatus”. Relevant News and ArticlesThis is a article which was published in JapanTimes where there is a new technology which was tested on deaf and blind patients , who were two different brands of headset were distributed for attendees to test: Seiko Epson’s Moverio and Olympus’ Meg. They both functioned in more or less the same way. This was a chance for the audience to experience the future of cinema in a barrier-free environment, so that everyone can enjoy going to the movies.159 
Figure 92: Analysis of Major Topics in Assistive Devices and Technologies for Visually and Hearing Impaired Persons Landscape for Seiko Epson MED-EL ELECTROMEDIZINISCHE GERAETE GMBHMED-EL Elektromedizinische Geräte Gesellschaft m.b.H. develops hearing implant solutions for children and adults. It offers cochlear implant and middle ear implant systems. The company was founded in 1977 and is based in Innsbruck, Austria. It has additional offices in Australasia, Austria, China, France, Germany, Hong Kong (Special Administrative Region of the People’s Republic of China), India, Indonesia, Italy, Japan, Korea, Malaysia, the Philippines, Portugal, Singapore, Spain, Thailand, Vietnam, the United Kingdom, and the United States, as well as Latin America and the Middle East.160 MED-EL Hearing Implant SolutionsThe MAESTRO Cochlear Implant System- MAESTRO consists of both an internal cochlear implant and an externally worn audio processor.161 Electric Acoustic Stimulation (EAS) is designed to fit the unique needs of individuals with partial deafness. EAS combines the advantages of acoustic amplification and cochlear implant technology in one system. The system consists of both an internal and an external component.162 The Vibrant Soundbridge, a unique middle ear implant system, has opened a world of new hearing possibilities for individuals who have not experienced an improvement with conventional hearing aids or cannot use them for medical reasons. This is often the case with permanent hearing loss after middle ear surgery or when hearing aids cannot be worn due to chronic ear canal inflammation (i.e., otitis externa). The Vibrant Soundbridge can be an effective solution for cases of mild to severe sensorineural hearing loss, as well as for conductive or mixed hearing loss.163 The Bonebridge, the world's first active bone conduction implant system, is intended for individuals with conductive or mixed hearing loss. With conductive or mixed hearing loss, sound cannot take the natural path through the outer and middle ear to the inner ear. With the Bonebridge, the sound waves are transmitted via bone conduction directly to the inner ear, where they are processed as natural sound.164 Relevant News and ArticlesThe company has filed an patent AU2012218042 which relates to acoustic signal processing for a hearing implant, and more particularly, to a speech coding methodology and system for a cochlear implant. The patent focusses on enhancing fine time structure transmission for hearing implant system.165 
Figure 93: Analysis of Major Topics in Assistive Devices and Technologies for Visually and Hearing Impaired Persons Landscape for Med El Electromedizinische Geraete GmbH. ALLERGANThe company has collaboration agreements with Molecular Partners AG; Spectrum Pharmaceuticals, Inc.; and Serenity Pharmaceuticals, LLC. Allergan, Inc. was founded in 1948 and is headquartered in Irvine, California.166 Allergan, Inc. is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. The Company’s segments include specialty pharmaceuticals, which produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and other prescription and over-the-counter skin care products; and urologic products and the medical devices segment, which produces a range of medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders; obesity intervention products, and facial aesthetics products. In April 2014, TauTona Group’s subsidiary Aline Aesthetics has completed the sale of its Aline hyaluronic acid (HA) thread technology to Allergan, Inc.167 Allergan products to treat a variety of eye conditions including glaucoma, dry eye, and external eye diseases. Today we are a global leader in this specialty area. Leading products in Allergan's eye care product portfolio include RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%, LUMIGAN® 0.01% and 0.03% (bimatoprost ophthalmic solution), and the REFRESH® Brand line of artificial tears.168, 169 An example of Allergan’s innovative contribution to this technology field can be seen in patent US8298570B2 entitled “Sustained release intraocular implants and related methods”. 
Figure 94: Analysis of Major Topics in Assistive Devices and Technologies for Visually and Hearing Impaired Persons Landscape for Allergan. Directory: edocs edocs -> Commissioner ajit pai edocs -> Before the Federal Communications Commission Washington, D edocs -> Before the Federal Communications Commission Washington, D edocs -> Before the Federal Communications Commission Washington, D edocs -> Before the Federal Communications Commission Washington, D edocs -> Before the Federal Communications Commission Washington, D edocs -> Federal Communications Commission fcc 15-77 Before the Federal Communications Commission edocs -> Statement of commissioner ajit pai Download 13.52 Mb. Share with your friends:
|